Drug Type T-lymphocyte cell therapy |
Synonyms NJA 001, NJA001 |
Target |
Action modulators |
Mechanism GPC3 modulators(Glypican-3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | United States | 01 Feb 2025 | |
Hepatocellular Carcinoma | Preclinical | United States | 01 Feb 2025 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 01 Feb 2025 |